Clinical Trials

Development of Memory Strategies in Aging
This research is studying the effect of healthy aging on the brain and effects of hypertension (higher than normal blood pressure levels) and Type 2 Diabetes (higher than normal levels of sugar in the blood) on memory performance and brain structure/function in people ages 35-45 or 60 years or older.
More Info

COBRE Research Study
Want to participate in cutting-edge research using MRI, MEG and EEG? We are looking for healthy men who a) Have no major history of head trauma, psychiatric or neurological disorders, substance abuse and less than a Bachelors degree, b) Are between the ages of 30 and 65, c) Have no metal in their body. If you qualify, you will be compensated for your time. Your confidentiality will be protected. You can receive pictures of your brain. By participating, you will be part of the effort that may help develop more effective treatments for schizophrenia. .If you are interested and fit the criteria above, please call 272-3507 or 272-9552UNM HRRC #07-325  
More Info

COBRE: A Multimodal Imaging Study
This Center for Biomedical Research Excellence (COBRE) will examine the neural mechanisms of schizophrenia by integrating multiple neuroimaging methods with psychiatric, neuropsychological and genetic testing. Participants will receive multiple brain scans throughout the course of this study. Participants will be compensated for their time. Please call 272-9544 for information.
Email for more information

Sensitivity to Intravenous Ethanol
This research will study how sensitivity to alcohol is related to brain functioning and behavior on tasks that measure response, inhibition and craving. You may be eligible to participate if you are over 21 and under 26 years of age. This study is being funded by the National Institute on Alcohol Abuse and Alcoholism.
More Info

Schizophrenia Trial
A multicenter, open-label study to assess hospitalization rates in adult subjects with schizophrenia treated prospectively for 6 months with Aripiprazole IM Depot compared with 6-month retrospective treatment with oral antipsychotics in a naturalistic community setting in the United States.

Participants must:

  • be between the ages of 18 and 65 years
  • have diagnosis of schizophrenia
  • have 1 inpatient psychiatric hospitalization within past 2 years
  • have no non-psychiatric hospitalization within past 4 weeks
  • currently be on oral antipsychotic treatment for past 7 months

Participants cannot:

  • have a history of head injury or other neurological disorder
  • have a current or past history of drug dependence
  • have significant extra pyramidal symptoms (tremors, akathisia) or tardive dyskinesia 

Roche Depression Trial
A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and safety of RO4995819 versus placebo, as adjunctive therapy in patients with major depressive disorder having inadequate response to ongoing antidepressant treatment. Protocol # BP25712

Participants must:

  • be between the ages of 18 and 65 years
  • have a diagnosis of depression
  • have an inadequate response to current antidepressant treatment with a selective serotonin reuptake inhibitor (SSRI) or a serotonin norepinephrine reuptake inhibitor (SNRI)

Participants cannot:

  • currently be receiving treatment with a combination of 3 or more antidepressants
  • have alcohol and/or substance abuse/dependence during the last 6 months
  • have a significant ongoing use of high doses of barbiturates, benzodiazepines or other anxiolytic drugs

Forest Depression Trial
A double-blind, placebo-controlled study of cariprazine as adjunctive therapy in major depressive disorder

Participants must:

  • be between the ages of 18 to 65 years
  • have a diagnosis of depression
  • have ongoing inadequate response to bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, sertraline, venlafaxine, or vilazodone

Participants cannot:

  • have any anticonvulsant/mood stabilizer, anxiolytic, benzodiazepine or other anti-depressant agent within one week of entering the study
  • have alcohol and/or substance abuse/dependence during the last 6 months
  • have a positive hepatitis C antibody on screening

Alcohol Dependence Trial
This study uses psychotherapy in combination with an experimental mind-altering medication, administered in a clinical setting, to see if this approach promotes recovery from problems with alcohol. Medical and psychiatric evaluations as well as treatment interventions are conducted free of charge.

Participants must:

  • be between the ages of 25 and 65
  • be alcohol dependent
  • be concerned about their drinking
  • have at least 4 heavy drinking days in the past 30 days

Targeted Transcranial Direct Current Stimulation to Enhance Speech-Language Treatment Outcomes in Persons with Chronic Post-Stroke Aphasia
The newly established Center for Brain Recovery and Repair has initiated new research for survivors of stroke in New Mexico and surrounding states. Many survivors of stroke have a speech and language disorder that can negatively impact quality of life, social participation, and return to work. This speech and language problem is called "aphasia", and can impact the ability to speak, understand, read, and/or write. New research combines proven speech-language treatments with cutting edge brain stimulation technology to study changes in the brain and language abilities.

The research is spearheaded by Jessica D. Richardson, an assistant professor and speech-language pathologist in the Department of Speech and Hearing Sciences and a new investigator for the Center for Brain Recovery and Repair. Dr. Richardson's research interests are focused on recovery from brain injury, development of effective treatment approaches, and development of outcome measures that better predict increased life participation after brain injury. For this project, she draws upon extensive experience with persons with stroke and aphasia, brain imaging, and brain stimulation.

If you have aphasia, or if you know of someone who has aphasia, contact us for more information about this study. See flyer for additional information.

Lab Contact Information
Jessica D. Richardson
University of New Mexico
Department of Speech and Hearing Sciences
Center for Brain Recovery and Repair
Email: jdrichardson@unm.edu
Website: http://www.jdrichslp.com/
Phone: 505/277-1765

Center for Brain Recovery and Repair Contact:
Darbi Gill, MS
Research Coordinator
505-925-4043


The University of New Mexico, Albuquerque, NM 87131, (505) 277-0111
Legal      Accessibility      HSC Intranet
Comments: HSC Web Team